T. Rowe Price Associates’s Entrada Therapeutics TRDA Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.64M	Buy	526,043 +198,620	+61%	+$2.28M	﹤0.01%	1321
2025 Q4	$3.37M	Sell	327,423 -33,103	-9%	-$279K	﹤0.01%	1531
2025 Q3	$2.09M	Sell	360,526 -2,206,952	-86%	-$12.9M	﹤0.01%	1710
2025 Q2	$17.3M	Sell	2,567,478 -169,289	-6%	-$1.36M	﹤0.01%	988
2025 Q1	$24.7M	Sell	2,736,767 -166,258	-6%	-$2.07M	﹤0.01%	900
2024 Q4	$50.2M	Sell	2,903,025 -146,547	-5%	-$2.66M	0.01%	752
2024 Q3	$48.7M	Sell	3,049,572 -84,886	-3%	-$1.34M	0.01%	765
2024 Q2	$44.7M	Buy	3,134,458 +381,101	+14%	+$5.42M	0.01%	757
2024 Q1	$39M	Sell	2,753,357 -256,316	-9%	-$3.62M	﹤0.01%	787
2023 Q4	$45.4M	Buy	3,009,673 +9,636	+0.3%	+$143K	0.01%	737
2023 Q3	$47.4M	Buy	3,000,037 +61,729	+2%	+$972K	0.01%	698
2023 Q2	$44.5M	Sell	2,938,308 -45,555	-2%	-$628K	0.01%	736
2023 Q1	$43.3M	Sell	2,983,863 -30,514	-1%	-$407K	0.01%	716
2022 Q4	$40.8M	Buy	3,014,377 +42,327	+1%	+$742K	0.01%	717
2022 Q3	$46.8M	Buy	2,972,050 +534,552	+22%	+$6.79M	0.01%	668
2022 Q2	$29.7M	Sell	2,437,498 -57,216	-2%	-$434K	﹤0.01%	1052
2022 Q1	$23.4M	Buy	2,494,714 +474,077	+23%	+$5.08M	﹤0.01%	1193
2021 Q4	$34.6M	Buy	+2,020,637	New	+$49M	﹤0.01%	1127